万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 库存:
大量
- 运输方式:
冻存运输
- 相关疾病:
腺癌
- 器官来源:
肺
- ATCC Number:
HTB-57™
- 生长状态:
贴壁生长
- 细胞形态:
上皮样
- 年限:
60 years
- 物种来源:
人
- 是否是肿瘤细胞:
0
| Designations: | SK-LU-1 | ||
| Depositors: | G Trempe, LJ Old | ||
| Biosafety Level: | 1 | ||
| Shipped: | frozen | ||
| Medium & Serum: | See Propagation | ||
| Growth Properties: | adherent | ||
| Organism: | Homo sapiens | ||
| Morphology: | epithelial |
||
| Source: | Organ: lung Disease: adenocarcinoma |
||
| Permits/Forms: | In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location. | ||
| Restrictions: | The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439. | ||
| Tumorigenic: | Yes | ||
| Antigen Expression: | Blood Type O; Rh+; HLA Aw24, Aw32, B27, Bw41 | ||
| DNA Profile (STR): | Amelogenin: X CSF1PO: 10 D13S317: 10 D16S539: 8 D5S818: 11 D7S820: 9 THO1: 7 TPOX: 8,10 vWA: 16,17 |
||
| Cytogenetic Analysis: | The stemline chromosome number is hypotetraploid, with the 2S component occurring at 4.4%. Marker chromosomes 1p, t(1q;11q); 11q+; t(13;?); 16q+; t(12q; 18q); M10; t(2q;13q); i(15); and ?t(xp;21q) occurred in all S metaphases, and t(1p;?); t(1p;14q); t(16;?), and t(14;21) occurred in some. In addition, 4 to 9 small markers of unidentifiable origin occurred frequently. Chromosome No. 7 was generally hexasomic, X chromosomes were disomic, and normal No. 15 was absent. No Y chromosome was detected in the QM stained preparation. | ||
| Isoenzymes: | AK-1, 1 ES-D, 2 G6PD, B GLO-I, 2 Me-2, 1 PGM1, 2 PGM3, 1 |
||
| Age: | 60 years | ||
| Gender: | female | ||
| Ethnicity: | Caucasian | ||
| Comments: | Mycoplasma contamination was detected and eliminated in 1971. | ||
| Propagation: | ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%. Temperature: 37.0°C |
||
| Subculturing: | Protocol:
Subcultivation Ratio: A subcultivation ratio of 1:2 is recommended Medium Renewal: Twice per week |
||
| Preservation: | Freeze medium: Complete growth medium, 95%; DMSO, 5% Storage temperature: liquid nitrogen vapor phase |
||
| Related Products: | Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003 recommended serum:ATCC 30-2020 |
||
| References: | 22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871 23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212 |
||
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验1. Inoculate the entire colony in 5 ml YPD culture O.N. or 12 hours 2. Dilute into YPA medium (1% yeast extract, 2% Bacto-peptone, 2%KOAC) to OD600~ 0.2, Vigorous shaking. 3. For ts mutants, ~15hours at 23C, others ~10 hours at 30C
适用标准:GB/T3536-91(克力夫兰开口杯法)GB/T267-88 产品说明: 本仪器采用当代先进技术,集机械、光学,电子及计算机技术于一体,结构紧凑。可自动完成石油产品开口闪点的测试,实验过程中的升温速率及扫描点火动作由微机控制自动进行,油气闪火时,检测系统自动捕捉并记录闪点温度。对闪点数据进行自动气压修正,并以规范的格式打印输出,还可根据需要重复打印数据。 本仪器可由计算机监控(无线/有线通讯方式,由用户选配)。 本仪器结构合理,性能稳定,操作简单,是理想的分析
One of the major obstacles in postoperative management of lung transplant recipients is differentiating between rejection and infection episodes. In addition, there are no reliable methods routinely to monitor lung allografts to ascertain
技术资料暂无技术资料 索取技术资料




